Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.
Nancolas B
,
Guo L
,
Zhou R
,
Nath K
,
Nelson DS
,
Leeper DB
,
Blair IA
,
Glickson JD
,
Halestrap AP
.
???displayArticle.abstract???
Lonidamine (LND) is an anti-tumour drug particularly effective at selectively sensitizing tumours to chemotherapy, hyperthermia and radiotherapy, although its precise mode of action remains unclear. It has been reported to perturb the bioenergetics of cells by inhibiting glycolysis and mitochondrial respiration, whereas indirect evidence suggests it may also inhibit L-lactic acid efflux from cells mediated by members of the proton-linked monocarboxylate transporter (MCT) family and also pyruvate uptake into the mitochondria by the mitochondrial pyruvate carrier (MPC). In the present study, we test these possibilities directly. We demonstrate that LND potently inhibits MPC activity in isolated rat liver mitochondria (Ki2.5 μM) and co-operatively inhibits L-lactate transport by MCT1, MCT2 and MCT4 expressed in Xenopus laevisoocytes with K0.5 and Hill coefficient values of 36-40 μM and 1.65-1.85 respectively. In rat heart mitochondria LND inhibited the MPC with similar potency and uncoupled oxidation of pyruvate was inhibited more effectively (IC50~ 7 μM) than other substrates including glutamate (IC50~ 20 μM). In isolated DB-1 melanoma cells 1-10 μM LND increased L-lactate output, consistent with MPC inhibition, but higher concentrations (150 μM) decreased L-lactate output whereas increasing intracellular [L-lactate] > 5-fold, consistent with MCT inhibition. We conclude that MPC inhibition is the most sensitive anti-tumour target for LND, with additional inhibitory effects on MCT-mediated L-lactic acid efflux and glutamine/glutamate oxidation. Together these actions can account for published data on the selective tumour effects of LND onL-lactate, intracellular pH (pHi) and ATP levels that can be partially mimicked by the established MPC and MCT inhibitor α-cyano-4-hydroxycinnamate (CHC).
BORST,
The pathway of glutamate oxidation by mitochondria isolated from different tissues.
1962, Pubmed
BORST,
The pathway of glutamate oxidation by mitochondria isolated from different tissues.
1962,
Pubmed
Baltazar,
Monocarboxylate transporters as targets and mediators in cancer therapy response.
2014,
Pubmed
Band,
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
1986,
Pubmed
Ben-Horin,
Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies.
1995,
Pubmed
Ben-Yoseph,
Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.
1998,
Pubmed
Bricker,
A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans.
2012,
Pubmed
Davidson,
Partial inhibition by cyclosporin A of the swelling of liver mitochondria in vivo and in vitro induced by sub-micromolar [Ca2+], but not by butyrate. Evidence for two distinct swelling mechanisms.
1990,
Pubmed
Floridi,
Energy metabolism of normal and lonidamine-treated Sertoli cells of rats.
1983,
Pubmed
Floridi,
Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
1981,
Pubmed
Floridi,
Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
1981,
Pubmed
Floridi,
Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria.
1983,
Pubmed
Floridi,
Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells.
1988,
Pubmed
Floridi,
Morphological and biochemical modifications of rat germ cell mitochondria induced by new antispermatogenic compounds: studies in vivo and in vitro.
1981,
Pubmed
Golding,
Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy.
2013,
Pubmed
Guo,
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine.
2016,
Pubmed
Halestrap,
Pyruvate and ketone-body transport across the mitochondrial membrane. Exchange properties, pH-dependence and mechanism of the carrier.
1978,
Pubmed
Halestrap,
The mitochondrial pyruvate carrier: has it been unearthed at last?
2012,
Pubmed
Halestrap,
The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
1975,
Pubmed
Halestrap,
Monocarboxylic acid transport.
2013,
Pubmed
Herzig,
Identification and functional expression of the mitochondrial pyruvate carrier.
2012,
Pubmed
Hildyard,
Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier.
2005,
Pubmed
Hill,
Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency.
1991,
Pubmed
Kim,
Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine.
1984,
Pubmed
Kim,
Potentiation of radiation effects on two murine tumors by lonidamine.
1986,
Pubmed
Manning Fox,
Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
2000,
Pubmed
,
Xenbase
Mardor,
Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.
2000,
Pubmed
Mathupala,
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
2009,
Pubmed
McCommis,
Mitochondrial pyruvate transport: a historical perspective and future research directions.
2015,
Pubmed
Nancolas,
Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity.
2015,
Pubmed
,
Xenbase
Nath,
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
2015,
Pubmed
Nath,
Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.
2015,
Pubmed
Nath,
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.
2013,
Pubmed
Ning,
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
1991,
Pubmed
Ovens,
AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.
2010,
Pubmed
,
Xenbase
Ovens,
The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein.
2010,
Pubmed
,
Xenbase
Pasdois,
The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia.
2011,
Pubmed
Prabhakara,
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
2008,
Pubmed
Price,
Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs.
1996,
Pubmed
Schell,
A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth.
2014,
Pubmed
Shearman,
The concentration of the mitochondrial pyruvate carrier in rat liver and heart mitochondria determined with alpha-cyano-beta-(1-phenylindol-3-yl)acrylate.
1984,
Pubmed
Shestov,
Metabolic network analysis of DB1 melanoma cells: how much energy is derived from aerobic glycolysis?
2013,
Pubmed
Silvestrini,
Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
1983,
Pubmed
Thomas,
The rôle of mitochondrial pyruvate transport in the stimulation by glucagon and phenylephrine of gluconeogenesis from L-lactate in isolated rat hepatocytes.
1981,
Pubmed
Tsai,
Alpha-keto acid dehydrogenase complexes. XX. A kinetic study of the pyruvate dehydrogenase complex from bovine kidney.
1973,
Pubmed
Wahl,
Regulation of intracellular pH in human melanoma: potential therapeutic implications.
2002,
Pubmed
Weinerman,
Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
1986,
Pubmed
Wilson,
Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70).
2005,
Pubmed
,
Xenbase
Wilson,
Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ.
2002,
Pubmed
Yang,
Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport.
2014,
Pubmed
Zhou,
Enhancement of hyperglycemia-induced acidification of human melanoma xenografts with inhibitors of respiration and ion transport.
2001,
Pubmed
